The European experience with conducting health technology assessments demonstrates the limitations of current approaches to comparative effectiveness, according to Biogen Inc. VP EU+ Market Access and Pricing Chris Leibman.
That could inform the way US payers approach valuing orphan drugs for reimbursement decisions, Leibman suggested at the Institute for Clinical and Economic Review stakeholder meeting on orphan drug pricing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?